Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil + Alpha Blocker for BPH
NCT00848081Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Tadalafil + Alpha-blocker with Placebo + Alpha-blocker (2 arms). Primary endpoint: Number of Men With Treatment-emergent Dizziness at 12 weeks. Started Mar 2009; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00848081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00848081.